Combining targeted therapy and immunotherapy with radiation for advanced kidney cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with recurrent or metastatic renal cancer, aiming to enhance local control of tumors through the combination of Stereotactic Ablative Radiotherapy (SABR) and systemic treatments like targeted therapy and anti-PD-1 immunotherapy. The study evaluates patients who have at least one lesion suitable for radiation therapy and are undergoing or planning to receive systemic therapy. By leveraging SABR's ability to precisely ablate tumors and potentially activate the immune response, the study seeks to improve progression-free survival rates beyond two years. The research is conducted at Peking University First Hospital and Peking University Third Hospital in Beijing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically confirmed renal cancer; diagnosed with recurrent or metastatic renal cancer via PET/CT or other whole-body imaging.
* Evaluated by the radiation oncology and imaging departments as having at least one lesion amenable to radiation therapy.
* Planning to undergo or currently receiving first-line or second-line targeted therapy combined with immunotherapy.
* Voluntarily agrees to participate in the study and signs an informed consent form.
* Male or female, aged ≥18 years (inclusive).
* Expected survival of ≥12 weeks.
* At least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
* European Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate cardiac, bone marrow, liver, and renal function.
* Willing and able to comply with the study procedures and follow-up schedule.

Exclusion Criteria:

* Extensive, multiple metastases;
* Presence of central nervous system metastases and/or carcinomatous meningitis.
* Toxicity from previous treatments not yet recovered to grade 0-1 (excluding grade 2 alopecia);
* Other severe, uncontrollable co-morbid conditions that could affect protocol compliance or confound interpretation of results, including active opportunistic or severe progressive infections, uncontrolled diabetes, uncontrolled hypertension, cardiovascular diseases (defined as New York Heart Association Class III or IV heart failure, second-degree or higher heart block, myocardial infarction within the last 12 months, unstable arrhythmias or angina, stroke within the last 6 months), or pulmonary diseases (interstitial pneumonia, obstructive pulmonary disease, and symptomatic bronchospasm history), deep vein thrombosis or pulmonary embolism within the last 6 months;
* Diagnosed with other malignancies within 5 years prior to enrollment, except:
* Localized low-risk prostate cancer (defined as stage ≤T2b, Gleason score ≤7, and PSA ≤20ng/mL at diagnosis, who have undergone curative treatment with no recurrence of prostate-specific antigen);
* Malignancies treated with a curative intent that are considered cured, including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with surgery;
* Pregnant or breastfeeding women;
* Positive HIV test result;
* Active hepatitis B or C infection;
* Active tuberculosis;
* Any other conditions, metabolic abnormalities, physical examination or laboratory findings that in the investigator's judgment might indicate an unsuitability for the study drug, could interfere with the interpretation of study results, or place the patient at high risk if they participate in the study;
* Estimated insufficient compliance with the clinical study.

Where it's running

• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Mingwei Ma, M.D.
• Email: dr.mingweima@stu.pku.edu.cn
• Phone: +86-15810160120

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CAIX PET/CT–guided radiation for clear cell kidney cancer

  This trial will try using CAIX-targeted PET/CT scans plus FDG PET/CT to guide focused stereotactic radiation alongside standard targeted therapy and anti‑PD‑1 immunotherapy for adults with recurrent or metastatic clear cell kidney cancer.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07540260

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Pelvic ultra-hypofractionated radiotherapy after surgery for high-risk endometrial cancer

  This trial tests whether giving 27.5 Gy in five sessions of pelvic radiotherapy after surgery is safe and feasible for high-risk endometrial cancer patients.

  Recruiting Instituto de Investigación Sanitaria Aragón · Zaragoza, Zaragoza · NCT07779109

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• Seeing what cancer patients eat during radiation treatment using a mobile food diary

  This study tests whether patients undergoing radiation therapy can consistently use a mobile food diary app to log their daily meals.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07682714

• Radiation therapy options compared for newly diagnosed gynecologic cancers

  This study tests whether proton therapy works as well as conventional photon therapy for endometrial and cervical cancers.

  Recruiting at 5 sites Phase 2 University of Maryland, Baltimore · Baltimore, Maryland and 4 other locations · NCT07415681

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.